Skip to content

Antimicrobial Resistance in Cirrhotic Patients

Antimicrobial Resistance Among Sputum Pathogens in Post Hepatitis Cirrhotic Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04915573
Enrollment
100
Registered
2021-06-07
Start date
2021-06-07
Completion date
2021-09-30
Last updated
2021-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis

Brief summary

Cirrhotic patients are more vulnerable to bacterial infection, and infection is one of the most common causes of acute liver disease decompensation.

Detailed description

Cirrhotic patients are more vulnerable to bacterial infection which is a common cause of acute liver disease decompensation. The aim of this study will characterize the antimicrobial resistance and distribution of bacteria isolated from chronic hepatic patients with pulmonary infections, as well as to evaluate the antimicrobial susceptibility of bacteria isolated from sputum.

Interventions

DIAGNOSTIC_TESTSpecimen

Sputum will be collected in clean disposable containers

Sponsors

Tanta University
CollaboratorOTHER
Mansoura University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1\. Adults' older than 18 years with clinical evidence of liver disease

Exclusion criteria

1. Pregnancy 2. Intensive care unite stay of more than 24 hours 3. Malignancy 4. Organ transplantation 5. Acquired immune deficiency syndrome

Design outcomes

Primary

MeasureTime frameDescription
Isolate IdentificationOne dayDistribution of bacterial isolates from sputum of cirrhotic patients expressed by frequency of each isolate
Antimicrobial resistanceOne dayAntimicrobial susceptibility testing to antibiotics determined by kirby-bauer disk diffusion

Countries

Egypt

Contacts

Primary ContactNoha Mansour, Ph.D
dr.nohamansour@gmail.com0020403315352

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026